Alveolar macrophages, resident phagocytic cells in the lung that derive from peripheral blood monocytes, are paradoxically ineffective in presenting antigen to T cells. We found that antigen presentation by alveolar macrophages could be restored by the addition of anti-CD28 mAb to cultures of T cells and macrophages, indicating that costimulation by alveolar macrophages via the CD28 pathway was defective. In addition, we found that alveolar macrophages activated with IFN-y failed to express B7-1 or B7-2 antigens, which normally ligate CD28 on T cells and provide a costimulatory signal required for the activation of T cells. These observations are the first to demonstrate the inability of a "professional" antigen-presenting cell type to effectively express the costimulatory molecules B7-1 and B7-2. Inasmuch as immune reactions within the lung are inevitably associated with inflammatory injury to pulmonary tissue, these observations suggest that reduced expression of B7-1 and B7-2 by alveolar macrophages may be advantageous, as a critical mechanism involved in the induction of peripheral tolerance to the abundance of antigens to which mucosal tissues are continuously exposed. (J. Clin. Invest. 1995Invest. . 95:1415Invest. -1421 
Introduction
Alveolar macrophages, resident phagocytic cells in the lung that derive from peripheral blood monocytes (1) , are paradoxically ineffective in presenting antigen to T cells. Because the lung is a gas exchange organ, it is exposed to large quantities of contaminants and antigens suspended in the air, yet, despite expressing normal levels of class II MHC antigens (2, 3) and having normal bactericidal activity, alveolar macrophages have
The purpose of these studies was to determine the reason for the failure of alveolar macrophages to effectively activate CD4 + T cells. Activation of CD4 + T cells requires at least two signaling events: one triggered by the ligation of the T cell receptor complex by antigen peptide/class II MHC on the antigen-presenting cells (APC);' the other signaling event generated by the ligation of costimulatory molecules on T cells (e.g., CD28) by counterreceptors (e.g., B7-2) on APC such as macrophages, B cells, and dendritic cells (7) (8) (9) (10) (11) . We found that human alveolar macrophages were deficient at presenting the antigen tetanus toxoid (TT) to autologous CD4+ T cells and were deficient at activating CD4+ T cells with anti-CD3 mAb. Antigen presentation by alveolar macrophages in both cases (with TT and anti-CD3 mAb) was restored by the addition of anti-CD28 mAb, indicating that costimulation by alveolar macrophages via the CD28 pathway was defective. Moreover, we found that alveolar macrophages activated with IFN-y failed to express B7-1 or B7-2 antigens, which normally ligate CD28 on T cells and provide a costimulatory signal required for the activation of T cells (9, 12, 13) . These results indicated that the inability of alveolar macrophages to present antigen effectively to T cells was due to the failure of alveolar macrophages to express sufficient quantities of the B7-1 and B7-2 antigens which resulted in a failure to provide effective costimulatory signaling to T cells.
These observations were the first to demonstrate the failure of a "professional" APC type to effectively express the costimulatory molecules B7-1 and B7-2 and were thus unexpected. However, inasmuch as immune reactions within the lung are inevitably associated with inflammatory injury to pulmonary tissue, our observations indicate that reduced expression of B7-1 and B7-2 by APC in the lung may be advantageous, as a critical mechanism that limits immune responses in the lung and in mucosal tissues which are continuously exposed to abundant quantities of antigen.
Methods
Study population. 15 healthy adult volunteers (7 male, 8 female) were selected, all without a history of smoking, asthma, or other respiratory disorders. The median age of study population was 26 yr (range, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] Fig. 1 shows that the addition of anti-IL-10 mAb had no effect on the T cell proliferative response induced by alveolar macrophages. Furthermore, addition of other cytokines such as IFN-y or GM-CSF or of IL-12, which in other systems have been shown to have beneficial effects on T cell proliferation (17) (18) (19) , also had no significant effect on the capacity of alveolar macrophages to induce T cell proliferation. Addition of IL-4 to the cultures or pretreatment of alveolar macrophages for 24 h with GM-CSF before culture also had no effect on T cell proliferation induced by alveolar macrophages (data not shown). These results suggest that inadequate amounts of GM-CSF or IL-12 were not directly involved in limiting the ability of alveolar macrophages to activate T cells.
Antigen presentation by alveolar macrophages is greatly enhanced by the addition ofanti-CD28 mAb. Inasmuch as crosslinking of the CD28 antigen on T cells has been shown to provide a potent costimulatory signal, we hypothesized that alveolar macrophages might be deficient in their capacity to cross-link CD28 on T cells. Anti-CD28 mAb was therefore added to cultures of alveolar macrophages and purified autologous T cells to provide help in cross-linking CD28 and stimulating T cell proliferation. Fig. 2 shows that alveolar macrophages were significantly less effective than peripheral blood monocytes/adherent cells in presenting TT to autologous T cells, but that in the presence of anti-CD28, alveolar macrophages became significantly more competent at inducing TT-specific proliferation. Addition of anti-CD28 mAb alone in the absence of antigen did not induce T cell proliferation. Similar results were obtained using soluble anti-CD3 mAb instead of TT to crosslink the T cell receptor/CD3 complex, in that alveolar macrophages, which can display anti-CD3 mAb via cell surface Fcy receptors, were ineffective at inducing anti-CD3 mAb mediated T cell proliferation. However, when anti-CD28 mAb was added to the cultures with soluble anti-CD3 mAb, the alveolar macrophages induced T cell proliferation that was equal in magnitude to that observed in response to anti-CD3 mAb with peripheral blood monocytes/adherent cells as APC (Fig. 2) . These results indicate that alveolar macrophages are ineffective at activating T cells because they cannot provide the CD28 costimulatory signal to T cells.
Alveolar macrophages are defective in their expression of the costimulator molecules B7-1 and B7-2. To explain the lack of CD28 costimulatory ability of alveolar macrophages, we directly examined the expression by alveolar macrophages of the cell surface molecules B7-2 and B7-1, which bind to CD28 on T cells. Fig. 3 shows that alveolar macrophages activated by overnight incubation in IFN-y did not express B7-2, although B7-2 was expressed at low levels on resting alveolar macrophages from 50% of subjects (absent on macrophages from the other 50% of subjects), when stained immediately after isolation. In contrast, peripheral blood monocytes activated with IFN-y expressed substantially increased quantities of B7-2, above the significant levels already expressed on resting monocytes. Expression of B7-1 on alveolar macrophages was also anomalous compared with that on peripheral blood phages from 50% of subjects), but any such expression was abolished after incubation of the macrophages with IFN-y (Fig.  3 ) or by culture with T cells and antigen (data not shown). In contrast, little or no B7-1 was expressed by resting peripheral blood monocytes (very low levels of B7-1 were present on monocytes from 50% of subjects), but expression was significantly enhanced after incubation of the monocytes with IFN--y ( Fig. 3 ) (8) and by culture with T cells and antigen (data not shown). Because IL-10 inhibits expression of B7-1 and B7-2 in monocytes (20, 21) , and because alveolar macrophages may produce significant quantities of IL-10, we cultured alveolar macrophages in the presence of anti-IL-10 mAb and IFN-y. After overnight culture, expression of B7-1 and B7-2 on alveolar macrophages was still absent (data not shown), consistent with our observations that anti-IL-10 mAb had minimal effect on the capacity of the macrophages to stimulate T cell proliferation (Fig. 1) , and indicating that B7-1 and B7-2 expression was not directly inhibited by elevated production of IL-10 in our cultures.
Discussion
The mechanisms that limit the capacity of alveolar macrophages to activate T cells are poorly understood, but could be due to the failure of alveolar macrophages to provide sufficient activation signals to T cells. Activation of CD4+ T cells, evidenced by proliferation and cytokine production, requires at least two signaling events: one triggered by the ligation and cross-linking of the T cell receptor complex by antigen peptide/class II MHC on the APC; the other signaling event generated by the ligation and cross-linking of T cell costimulatory molecules, e.g., CD28, by counterreceptors (e.g., B7-1 and B7-2) on APC such as macrophages, B cells, and dendritic cells (7, 8, 11, 22) . The ligation of the CD28 antigen on T cells provides an extremely important signal that upregulates the synthesis of IL-2 and IFN--y in T cells (23) (24) (25) and prevents the induction of T cell anergy or tolerance (12, 13, [26] [27] [28] .
In our studies, we examined the failure of alveolar macrophages to activate T cells and determined the role of B7-1 and B7-2 on alveolar macrophages in this failure. We found that the inability of alveolar macrophages to activate T cells was not due to a failure to process antigen, since alveolar macrophages could induce a TT-specific proliferative response when a costimulatory signal was provided by anti-CD28 mAb. Furthermore, the inability of alveolar macrophages to activate T cells was not due to a failure to process antigen, because alveolar macrophages could not activate T cells via anti-CD3 mAb, which directly ligates the T cell receptor/CD3 complex and is independent of antigen processing. Inasmuch as the failure of alveolar macrophages to activate T cells was reversed by the addition of anti-CD28 mAb, and since activated alveolar macrophages failed to express B7-1 and B7-2 antigens, we suggest that the sole reason for the failure of alveolar macrophages to activate T cells is their inability to provide costimulation via the CD28 pathway.
The mechanism by which alveolar macrophages, long-lived phagocytic cells that derive from peripheral blood monocytes (1), paradoxically limit their expression of B7-1 and B7-2 is not clear. IL-10 has been shown previously to downregulate B7-1 expression on macrophages (20, 21) . Therefore the production of IL-10 in the lung might play a role in downregulating B7 expression on alveolar macrophages, and in downregulating inflammation, as it does in other tissues, particularly in the intestinal tract, where recent studies indicate that ablation of IL-10 expression results in severe inflammatory bowel disease (29) . In our experiments the addition of anti-IL-10 mAb to cultures of alveolar macrophages for > 24 h did not enhance the expression of B7-1 and B7-2 and did not enhance antigen presentation by alveolar macrophages. It is possible, however, that anti-IL-10 mAb had no effect in vitro because a potent IL-10 signal occurred in vivo, or that more prolonged in vitro We observed that resting alveolar macrophages from some individuals expressed low levels of B7-1 or B7-2 (Fig. 3) . (3, 5) . However, in our studies, expression of B7-1 or B7-2 by resting macrophages was ablated by activation with IFN-'y, which is in direct contrast with our results with peripheral blood monocytes, which expressed increased quantities of B7-1 and B7-2 when activated (7, 9, 10 (26, (30) (31) (32) . Although these mucosal surfaces are continuously exposed to abundant quantities of antigen, immune responsiveness must be restricted or downregulated at these sites since inflammatory reactions inevitably produce significant damage to the mucosal surface. The mechanisms responsible for the induction of oral/mucosal tolerance have not been fully elucidated, but are thought to involve the generation of active suppression or the induction of clonal anergy (33) (34) (35) (36) (37) (38) . Although it is thought that antigen dose can modulate oral tolerance (33) , in view of the fact that antigen presentation in vitro in the absence of B7 costimulation results in T cell unresponsiveness or tolerance (12, 13, (26) (27) (28) , we suggest that the principal mechanism that regulates the induction of peripheral tolerance in vivo (in lung and bronchial-associated lymphoid tissue or in gut-associated lymphoid tissue [30, 39] ) is the restriction of B7-1 and B7-2 expression on APC. Moreover, we suggest that alveolar macrophages, which have reduced expression of B7-1 and B7-2, play a major role in downregulating immune responses in the lung and in inducing immunological tolerance to inhaled antigens. In this regard, preliminary studies in our laboratory indicate that alveolar macrophages can indeed induce antigen-specific tolerance in peripheral blood T cells (Hwang, P. T., et al., manuscript in preparation).
Since alveolar macrophages are limited in their capacity to initiate inflammatory responses, how are antigen-specific immune responses elicited in the lung? This is not necessarily a problem, since dendritic cells, which are present in the peribronchial connective tissues (but not on the epithelial surface in the lung nor in bronchial alveolar lavage fluid [40] ), as well as neutrophils, can be recruited into the lung quite readily (41) .
However, the balance between activation of immune responses by dendritic cells and the inhibition of inflammatory responses by alveolar macrophages is precarious: overly zealous inhibition may result in overwhelming infection, whereas insufficient inhibition may result in allergic or inflammatory disease. Nonetheless, alveolar macrophages appear well suited to defend the lung, since they are very efficient at phagocytizing antigen and microorganisms but at the same time are ineffective at activating T cells and initiating inflammatory responses.
